Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan
出版年份 2023 全文链接
标题
Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan
作者
关键词
-
出版物
Frontiers in Neurology
Volume 14, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2023-07-07
DOI
10.3389/fneur.2023.1220285
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Response to erenumab assessed by Headache Impact Test‐6 is modulated by genetic factors and arterial hypertension: An explorative cohort study
- (2023) Chiara Zecca et al. EUROPEAN JOURNAL OF NEUROLOGY
- Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis
- (2023) Roberta Messina et al. CEPHALALGIA
- Predictors of response to galcanezumab in patients with chronic migraine: a real-world prospective observational study
- (2023) Hyoung Cheol Lee et al. NEUROLOGICAL SCIENCES
- Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b/3 trials in Japanese and Korean patients
- (2022) Takao Takeshima et al. JOURNAL OF HEADACHE AND PAIN
- Migraine
- (2022) Michel D. Ferrari et al. Nature Reviews Disease Primers
- Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study
- (2022) Patricia Pozo-Rosich et al. CURRENT MEDICAL RESEARCH AND OPINION
- Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
- (2022) Maurice T. Driessen et al. JOURNAL OF HEADACHE AND PAIN
- Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
- (2022) Piero Barbanti et al. JOURNAL OF HEADACHE AND PAIN
- European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update
- (2022) Simona Sacco et al. JOURNAL OF HEADACHE AND PAIN
- A study to investigate the prevalence of headache disorders and migraine among people registered in a health insurance association in Japan
- (2022) Fumihiko Sakai et al. JOURNAL OF HEADACHE AND PAIN
- Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial
- (2022) Roberto De Icco et al. JOURNAL OF HEADACHE AND PAIN
- Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients
- (2022) Piero Barbanti et al. JOURNAL OF HEADACHE AND PAIN
- Role of Calcitonin Gene-Related Peptide on the Gastrointestinal Symptoms of Migraine—Clinical Considerations: A Narrative Review
- (2022) Jessica Ailani et al. NEUROLOGY
- Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis
- (2022) Tsubasa Takizawa et al. BMC Neurology
- Migraine: epidemiology and systems of care
- (2021) Messoud Ashina et al. LANCET
- Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients
- (2021) Fumihiko Sakai et al. HEADACHE
- Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients
- (2021) Fumihiko Sakai et al. HEADACHE
- Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3‐month observational, longitudinal, cohort, multicenter, Italian real‐life study
- (2021) Fabrizio Vernieri et al. EUROPEAN JOURNAL OF NEUROLOGY
- Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States
- (2021) Peter McAllister et al. JOURNAL OF HEADACHE AND PAIN
- Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans
- (2020) Tessa de Vries et al. PHARMACOLOGY & THERAPEUTICS
- A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects
- (2018) Orit Cohen-Barak et al. CEPHALALGIA
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started